$SSY
SUNLINK HEALTH SYSTEMS INC

2024 Q1 Form 10-Q Financial Statement

#000095017024014629 Filed on February 13, 2024

View on sec.gov

Income Statement

Concept 2024 Q1 2023 Q4
Revenue $7.462M $8.510M
YoY Change -35.3% -40.87%
Cost Of Revenue $4.339M $4.761M
YoY Change -8.75% 5.38%
Gross Profit $3.123M $3.749M
YoY Change -53.92% -62.03%
Gross Profit Margin 41.85% 44.05%
Selling, General & Admin $3.045M $3.080M
YoY Change -48.97% -50.27%
% of Gross Profit 97.5% 82.16%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization $342.0K $318.0K
YoY Change -17.39% -17.83%
% of Gross Profit 10.95% 8.48%
Operating Expenses $3.976M $4.182M
YoY Change -47.35% -46.62%
Operating Profit -$853.0K -$433.0K
YoY Change 10.21% -121.23%
Interest Expense $19.00K $29.00K
YoY Change -53.66% 222.22%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$834.0K -$404.0K
YoY Change 13.78% -119.7%
Income Tax -$10.00K $3.000K
% Of Pretax Income
Net Earnings -$1.396M -$3.075M
YoY Change 83.2% -257.61%
Net Earnings / Revenue -18.71% -36.13%
Basic Earnings Per Share -$0.20 -$0.44
Diluted Earnings Per Share -$0.20 -$0.44
COMMON SHARES
Basic Shares Outstanding 7.041M 7.041M
Diluted Shares Outstanding 7.041K 7.040K

Balance Sheet

Concept 2024 Q1 2023 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $1.211M $2.055M
YoY Change -77.5% -60.14%
Cash & Equivalents $1.211M $2.055M
Short-Term Investments
Other Short-Term Assets $5.116M $7.001M
YoY Change 193.85% 279.66%
Inventory $1.561M $1.593M
Prepaid Expenses
Receivables $3.078M $3.061M
Other Receivables $0.00 $0.00
Total Short-Term Assets $10.97M $13.71M
YoY Change -17.57% -8.75%
LONG-TERM ASSETS
Property, Plant & Equipment $2.903M $2.921M
YoY Change -65.42% -65.34%
Goodwill
YoY Change
Intangibles $1.180M $1.180M
YoY Change -0.17% -0.67%
Long-Term Investments
YoY Change
Other Assets $503.0K $327.0K
YoY Change -16.58% -34.07%
Total Long-Term Assets $5.178M $5.077M
YoY Change -53.46% -54.45%
TOTAL ASSETS
Total Short-Term Assets $10.97M $13.71M
Total Long-Term Assets $5.178M $5.077M
Total Assets $16.14M $18.79M
YoY Change -33.92% -28.21%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.532M $1.420M
YoY Change -2.36% -24.31%
Accrued Expenses $1.864M $1.969M
YoY Change -28.72% -39.56%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00
YoY Change -100.0%
Total Short-Term Liabilities $3.959M $5.228M
YoY Change -15.35% -7.19%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $73.00K $118.0K
YoY Change -62.94% -35.16%
Total Long-Term Liabilities $577.0K $555.0K
YoY Change -39.52% -43.08%
TOTAL LIABILITIES
Total Short-Term Liabilities $3.959M $5.228M
Total Long-Term Liabilities $577.0K $555.0K
Total Liabilities $4.536M $5.783M
YoY Change -19.45% -12.48%
SHAREHOLDERS EQUITY
Retained Earnings -$2.810M -$1.414M
YoY Change -163.42% -127.23%
Common Stock $14.27M $14.27M
YoY Change 0.04% 0.04%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $11.61M $13.00M
YoY Change
Total Liabilities & Shareholders Equity $16.14M $18.79M
YoY Change -33.92% -28.21%

Cashflow Statement

Concept 2024 Q1 2023 Q4
OPERATING ACTIVITIES
Net Income -$1.396M -$3.075M
YoY Change 83.2% -257.61%
Depreciation, Depletion And Amortization $342.0K $318.0K
YoY Change -17.39% -17.83%
Cash From Operating Activities -$1.062M -$393.0K
YoY Change -275.25% -171.98%
INVESTING ACTIVITIES
Capital Expenditures $282.0K $369.0K
YoY Change -24.6% -29.98%
Acquisitions
YoY Change
Other Investing Activities $500.0K $0.00
YoY Change -100.0%
Cash From Investing Activities $218.0K -$369.0K
YoY Change -158.29% -1.86%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 -3.000K
YoY Change -100.0% -108.57%
NET CHANGE
Cash From Operating Activities -1.062M -393.0K
Cash From Investing Activities 218.0K -369.0K
Cash From Financing Activities 0.000 -3.000K
Net Change In Cash -844.0K -765.0K
YoY Change -473.45% -473.17%
FREE CASH FLOW
Cash From Operating Activities -$1.062M -$393.0K
Capital Expenditures $282.0K $369.0K
Free Cash Flow -$1.344M -$762.0K
YoY Change -679.31% -4110.53%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--06-30
dei Entity Central Index Key
EntityCentralIndexKey
0000096793
dei Amendment Flag
AmendmentFlag
false
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Common Stock No Par Value
CommonStockNoParValue
CY2023Q2 us-gaap Common Stock No Par Value
CommonStockNoParValue
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-12-31
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
1-12607
dei Entity Registrant Name
EntityRegistrantName
SUNLINK HEALTH SYSTEMS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
GA
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
31-0621189
dei Entity Address Address Line1
EntityAddressAddressLine1
900 Circle 75 Parkway
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 690
dei Entity Address City Or Town
EntityAddressCityOrTown
Atlanta
dei Entity Address State Or Province
EntityAddressStateOrProvince
GA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
30339
dei City Area Code
CityAreaCode
770
dei Local Phone Number
LocalPhoneNumber
933-7000
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
7040603
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2055000
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4486000
CY2023Q4 us-gaap Receivables Net Current
ReceivablesNetCurrent
3061000
CY2023Q2 us-gaap Receivables Net Current
ReceivablesNetCurrent
2592000
CY2023Q4 us-gaap Inventory Net
InventoryNet
1593000
CY2023Q2 us-gaap Inventory Net
InventoryNet
1628000
CY2023Q4 us-gaap Assets Held For Sale Not Part Of Disposal Group Current
AssetsHeldForSaleNotPartOfDisposalGroupCurrent
5328000
CY2023Q2 us-gaap Assets Held For Sale Not Part Of Disposal Group Current
AssetsHeldForSaleNotPartOfDisposalGroupCurrent
1920000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1673000
CY2023Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1648000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
13710000
CY2023Q2 us-gaap Assets Current
AssetsCurrent
12274000
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
12050000
CY2023Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
11259000
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
9129000
CY2023Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
8542000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2921000
CY2023Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2717000
CY2023Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
1180000
CY2023Q2 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
1180000
CY2023Q4 ssy Assetsheldforsalenotpartofdisposalgroupnoncurrent
Assetsheldforsalenotpartofdisposalgroupnoncurrent
0
CY2023Q2 ssy Assetsheldforsalenotpartofdisposalgroupnoncurrent
Assetsheldforsalenotpartofdisposalgroupnoncurrent
5812000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
649000
CY2023Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
798000
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
327000
CY2023Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
487000
CY2023Q4 us-gaap Assets Noncurrent Other Than Noncurrent Investments And Property Plant And Equipment
AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment
2156000
CY2023Q2 us-gaap Assets Noncurrent Other Than Noncurrent Investments And Property Plant And Equipment
AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment
8277000
CY2023Q4 us-gaap Assets
Assets
18787000
CY2023Q2 us-gaap Assets
Assets
23268000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1420000
CY2023Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
1067000
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
924000
CY2023Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1027000
CY2023Q4 ssy Current Liabilities Held For Sale
CurrentLiabilitiesHeldForSale
1839000
CY2023Q2 ssy Current Liabilities Held For Sale
CurrentLiabilitiesHeldForSale
1326000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
331000
CY2023Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
334000
CY2023Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
714000
CY2023Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
1115000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
5228000
CY2023Q2 us-gaap Liabilities Current
LiabilitiesCurrent
4869000
CY2023Q4 ssy Professional Liability Risks Non Current
ProfessionalLiabilityRisksNonCurrent
105000
CY2023Q2 ssy Professional Liability Risks Non Current
ProfessionalLiabilityRisksNonCurrent
138000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
332000
CY2023Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
481000
CY2023Q4 ssy Noncurrent Liabilities Held For Sale
NoncurrentLiabilitiesHeldForSale
0
CY2023Q2 ssy Noncurrent Liabilities Held For Sale
NoncurrentLiabilitiesHeldForSale
192000
CY2023Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
118000
CY2023Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
171000
CY2023Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
555000
CY2023Q2 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
982000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2000000
CY2023Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2000000
CY2023Q4 us-gaap Preferred Stock Share Subscriptions
PreferredStockShareSubscriptions
2000000
CY2023Q2 us-gaap Preferred Stock Share Subscriptions
PreferredStockShareSubscriptions
2000000
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2023Q2 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
7041000
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
7041000
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
7032000
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
7032000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
3521000
CY2023Q2 us-gaap Common Stock Value
CommonStockValue
3516000
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
10747000
CY2023Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
10746000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1414000
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
3005000
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
150000
CY2023Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
150000
CY2023Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
13004000
CY2023Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
17417000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
18787000
CY2023Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
23268000
CY2023Q4 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
8510000
CY2022Q4 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
10640000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
17065000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
18089000
CY2023Q4 us-gaap Labor And Related Expense
LaborAndRelatedExpense
2668000
CY2022Q4 us-gaap Labor And Related Expense
LaborAndRelatedExpense
2481000
us-gaap Labor And Related Expense
LaborAndRelatedExpense
5285000
us-gaap Labor And Related Expense
LaborAndRelatedExpense
5004000
CY2023Q4 us-gaap Supplies Expense
SuppliesExpense
39000
CY2022Q4 us-gaap Supplies Expense
SuppliesExpense
35000
us-gaap Supplies Expense
SuppliesExpense
73000
us-gaap Supplies Expense
SuppliesExpense
65000
CY2023Q4 us-gaap Other Cost And Expense Operating
OtherCostAndExpenseOperating
784000
CY2022Q4 us-gaap Other Cost And Expense Operating
OtherCostAndExpenseOperating
720000
us-gaap Other Cost And Expense Operating
OtherCostAndExpenseOperating
1690000
us-gaap Other Cost And Expense Operating
OtherCostAndExpenseOperating
1253000
CY2023Q4 us-gaap Operating Lease Expense
OperatingLeaseExpense
92000
CY2022Q4 us-gaap Operating Lease Expense
OperatingLeaseExpense
92000
us-gaap Operating Lease Expense
OperatingLeaseExpense
183000
us-gaap Operating Lease Expense
OperatingLeaseExpense
184000
CY2023Q4 us-gaap Depreciation And Amortization
DepreciationAndAmortization
318000
CY2022Q4 us-gaap Depreciation And Amortization
DepreciationAndAmortization
288000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
618000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
557000
CY2023Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-433000
CY2022Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
2270000
us-gaap Operating Income Loss
OperatingIncomeLoss
-883000
us-gaap Operating Income Loss
OperatingIncomeLoss
1653000
CY2023Q4 us-gaap Gains Losses On Sales Of Assets
GainsLossesOnSalesOfAssets
0
CY2022Q4 us-gaap Gains Losses On Sales Of Assets
GainsLossesOnSalesOfAssets
1000
us-gaap Gains Losses On Sales Of Assets
GainsLossesOnSalesOfAssets
2000
us-gaap Gains Losses On Sales Of Assets
GainsLossesOnSalesOfAssets
13000
CY2023Q4 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
29000
CY2022Q4 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
5000
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
51000
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
5000
CY2023Q4 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-404000
CY2022Q4 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
2276000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-830000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
1671000
CY2023Q4 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
3000
CY2022Q4 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-1000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
5000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-1000
CY2023Q4 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-407000
CY2022Q4 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
2277000
us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-835000
us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
1672000
CY2023Q4 us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
-2668000
CY2022Q4 us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
-326000
us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
-3584000
us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
-1279000
CY2023Q4 us-gaap Net Income Loss
NetIncomeLoss
-3075000
CY2022Q4 us-gaap Net Income Loss
NetIncomeLoss
1951000
us-gaap Net Income Loss
NetIncomeLoss
-4419000
us-gaap Net Income Loss
NetIncomeLoss
393000
CY2023Q4 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
0
CY2022Q4 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
0
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
0
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
0
CY2023Q4 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-3075000
CY2022Q4 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
1951000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-4419000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
393000
CY2023Q4 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.06
ssy Expenditures For Property Plant And Equipment Discontinued Operations
ExpendituresForPropertyPlantAndEquipmentDiscontinuedOperations
318000
us-gaap Proceeds From Sale Of Other Assets Investing Activities
ProceedsFromSaleOfOtherAssetsInvestingActivities
5000
us-gaap Proceeds From Sale Of Other Assets Investing Activities
ProceedsFromSaleOfOtherAssetsInvestingActivities
213000
CY2022Q4 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
0.32
us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.12
us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
0.24
CY2023Q4 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-0.06
CY2022Q4 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
0.32
us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-0.12
us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
0.24
CY2023Q4 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
-0.38
CY2022Q4 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
-0.05
us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
-0.51
us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
-0.18
CY2023Q4 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
-0.38
CY2022Q4 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
-0.05
us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
-0.51
us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
-0.18
CY2023Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.44
CY2022Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.28
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.63
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.06
CY2023Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.44
CY2022Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.28
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.63
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.06
CY2023Q4 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7040
CY2022Q4 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7031
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7039
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7007
CY2023Q4 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7040
CY2022Q4 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7033
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7039
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7010
CY2023Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
17417000
CY2023Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
6000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-1344000
CY2023Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
16079000
CY2023Q4 us-gaap Net Income Loss
NetIncomeLoss
-3075000
CY2023Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
13004000
CY2022Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
19120000
CY2022Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
48000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-1558000
CY2022Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
17610000
CY2022Q4 us-gaap Net Income Loss
NetIncomeLoss
1951000
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
19561000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1530000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-724000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
824000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
833000
ssy Expenditures For Property Plant And Equipment Discontinued Operations
ExpendituresForPropertyPlantAndEquipmentDiscontinuedOperations
74000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-893000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-938000
ssy Proceeds From Share Option Exercises
ProceedsFromShareOptionExercises
6000
ssy Proceeds From Share Option Exercises
ProceedsFromShareOptionExercises
48000
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
14000
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
24000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-8000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
24000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-2431000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-1638000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4486000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
6794000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2055000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
5156000
ssy Interest Paid Received Net
InterestPaidReceivedNet
-51000
ssy Interest Paid Received Net
InterestPaidReceivedNet
-6000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
105000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
-32000
ssy Right Of Use Asset Obtained In Exchange For Lease Liability
RightOfUseAssetObtainedInExchangeForLeaseLiability
18000
ssy Right Of Use Asset Obtained In Exchange For Lease Liability
RightOfUseAssetObtainedInExchangeForLeaseLiability
24000
us-gaap Nature Of Operations
NatureOfOperations
<p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Note 2. – Business Operations</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> The Company’s continuing operations are composed of a pharmacy business and an information technology (“IT”) business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> The pharmacy business, is composed of four operational areas conducted in three locations in southwest Louisiana:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Symbol',serif;min-width:fit-content;">· </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Retail pharmacy products and services, consisting of retail pharmacy sales.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Symbol',serif;min-width:fit-content;">· </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Institutional pharmacy services consisting of the provision of specialty and non-specialty pharmaceutical and biological products to institutional clients or to patients in institutional settings, such as extended care and rehabilitation centers, nursing homes, assisted living facilities, behavioral and specialty hospitals, hospice, and correctional facilities.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Symbol',serif;min-width:fit-content;">· </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Non-institutional Pharmacy services consisting of the provision of specialty and non-specialty pharmaceutical and biological products to clients or patients in non-institutional settings including private residential homes.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Symbol',serif;min-width:fit-content;">· </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Durable medical equipment products and services (“DME”), consisting primarily of the sale and rental of products for institutional clients or to patients in institutional settings and patient-administered home care.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Tahoma',sans-serif;min-width:fit-content;"></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><br/></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Symbol',serif;min-width:fit-content;"> A </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">subsidiary, SunLink Health Systems Technology (“SHST Technology”), provides information technology (“IT”) services to outside customers and to SunLink subsidiaries. The Company also owns a subsidiary which owns approximately twenty-five (25) acres of unimproved land in Ellijay, Georgia.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Tahoma',sans-serif;min-width:fit-content;"></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><br/><br/></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#212529;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Series C Redeemable Preferred Shares</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> On August 2, 2023, the Board of SunLink declared a non-cash dividend per Common Share of one fractional interest in one of the Corporation’s Series C Redeemable Preferred Shares (the “Series C Preferred</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Shares” and each such fraction of a Series C Preferred Share, a “Series C Fractional Interest”). </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Each of the </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">7,032</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Series C Preferred Shares issued was entitled to one million (1,000,000) votes and each Series C Fractional Interest in a Series C Preferred Share was entitled to one thousand (1,000) votes out of such one million votes.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Series C Fractional Interests could not be transferred separately from the Common Shares and were represented by the Common Shares. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Each Common Share was entitled to one (1) vote as a Common Share and also one thousand (1,000) votes for the corresponding Series C Fractional Interest thereon, on each matter properly brought before a special shareholders’ meeting which was held on October 19, 2023 and at which the Corporation was reincorporated from the state of Ohio to Georgia (the “Special Meeting”).</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> A further description of the Series C Preferred Shares and the Series C Fractional Interests and the terms and provisions thereof is set forth in the Company’s Current Report on Form 8-K filed with the SEC on August 11, 2023.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#212529;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">COVID-19 Pandemic and CARES Act Funding</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company continued to experience adverse after-effects of the COVID-19 pandemic in the quarter ended December 31, 2023 and believes such effects will likely continue to affect its assets and operations in the foreseeable future particularly salaries and wages pressure, workforce shortages, supply chain disruption and broad inflationary pressures. Our ability to make estimates of any such continuing effects of evolving strains of COVID-19 on future revenues, expenses or changes in accounting judgments that have had or are reasonably likely to have a material effect on our financial statements is very limited, depending as they do on the severity and length thereof; as well as any further government actions and/or regulatory changes intended to address such effects.</span></p>
CY2023Q4 ssy Transaction Expenses
TransactionExpenses
58000
CY2023Q4 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
0
CY2022Q4 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
0
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
0
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
0
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
9000
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
77452
CY2023Q4 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
8510000
CY2022Q4 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
10640000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
17065000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
18089000
CY2023Q4 ssy Reversed Accrued Sales Tax
ReversedAccruedSalesTax
59000
CY2022Q4 ssy Increase In Revenue
IncreaseInRevenue
2615000
ssy Reversed Accrued Sales Tax
ReversedAccruedSalesTax
380000
ssy Increase In Revenue
IncreaseInRevenue
2615
CY2023Q2 us-gaap Financing Receivable Allowance For Credit Losses
FinancingReceivableAllowanceForCreditLosses
532000
CY2023Q3 us-gaap Financing Receivable Change In Method Credit Loss Expense Reversal
FinancingReceivableChangeInMethodCreditLossExpenseReversal
79000
CY2023Q3 us-gaap Financing Receivable Allowance For Credit Losses Write Offs
FinancingReceivableAllowanceForCreditLossesWriteOffs
203000
CY2023Q3 us-gaap Financing Receivable Allowance For Credit Losses
FinancingReceivableAllowanceForCreditLosses
408000
CY2023Q4 us-gaap Financing Receivable Change In Method Credit Loss Expense Reversal
FinancingReceivableChangeInMethodCreditLossExpenseReversal
67000
CY2023Q4 us-gaap Financing Receivable Allowance For Credit Losses Write Offs
FinancingReceivableAllowanceForCreditLossesWriteOffs
104000
CY2023Q4 us-gaap Financing Receivable Allowance For Credit Losses
FinancingReceivableAllowanceForCreditLosses
371000
CY2023Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
1180000
CY2023Q2 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
1180000
CY2023Q4 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
0
CY2022Q4 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
6000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
0
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
13000
CY2023Q4 ssy Finance Lease Obligations
FinanceLeaseObligations
0
CY2023Q2 ssy Finance Lease Obligations
FinanceLeaseObligations
14000
CY2023Q4 us-gaap Long Term Debt And Capital Lease Obligations Current
LongTermDebtAndCapitalLeaseObligationsCurrent
0
CY2023Q2 us-gaap Long Term Debt And Capital Lease Obligations Current
LongTermDebtAndCapitalLeaseObligationsCurrent
14000
CY2023Q4 us-gaap Long Term Debt And Capital Lease Obligations
LongTermDebtAndCapitalLeaseObligations
0
CY2023Q2 us-gaap Long Term Debt And Capital Lease Obligations
LongTermDebtAndCapitalLeaseObligations
0
CY2023Q4 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
3000
CY2022Q4 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-1000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
5000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-1000
CY2023Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
9163000
CY2023Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0
CY2023Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
69000
CY2023Q4 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
28082000
CY2023Q4 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
28082000
ssy Net Operating Loss Carry Forwards Expire Period
NetOperatingLossCarryForwardsExpirePeriod
2023 through fiscal year 2038
CY2023Q4 us-gaap Operating Lease Cost
OperatingLeaseCost
85000
CY2022Q4 us-gaap Operating Lease Cost
OperatingLeaseCost
85000
us-gaap Operating Lease Cost
OperatingLeaseCost
170000
us-gaap Operating Lease Cost
OperatingLeaseCost
170000
CY2023Q4 ssy Short Term Lease Cost Income
ShortTermLeaseCostIncome
7000
CY2022Q4 ssy Short Term Lease Cost Income
ShortTermLeaseCostIncome
7000
ssy Short Term Lease Cost Income
ShortTermLeaseCostIncome
12000
ssy Short Term Lease Cost Income
ShortTermLeaseCostIncome
13000
CY2023Q4 ssy Operating Variable Lease Cost
OperatingVariableLeaseCost
0
CY2022Q4 ssy Operating Variable Lease Cost
OperatingVariableLeaseCost
0
ssy Operating Variable Lease Cost
OperatingVariableLeaseCost
1000
ssy Operating Variable Lease Cost
OperatingVariableLeaseCost
1000
CY2023Q4 us-gaap Operating Lease Expense
OperatingLeaseExpense
92000
CY2022Q4 us-gaap Operating Lease Expense
OperatingLeaseExpense
92000
us-gaap Operating Lease Expense
OperatingLeaseExpense
183000
us-gaap Operating Lease Expense
OperatingLeaseExpense
184000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
649000
CY2023Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
798000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
331000
CY2023Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
334000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
332000
CY2023Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
481000
CY2023Q4 us-gaap Operating Lease Payments
OperatingLeasePayments
85000
CY2022Q4 us-gaap Operating Lease Payments
OperatingLeasePayments
85000
us-gaap Operating Lease Payments
OperatingLeasePayments
170000
us-gaap Operating Lease Payments
OperatingLeasePayments
170000
CY2023Q4 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0
CY2022Q4 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
9000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
18000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
16000
CY2023Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y21D
CY2022Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y11M19D
CY2023Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y21D
CY2023Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y11M19D
CY2023Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0098
CY2022Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0102
CY2023Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0098
CY2022Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0102
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
336000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
298000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
31000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
5000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
0
CY2023Q4 ssy Lessee Operating Lease Liability Payments Due After Year Four
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
0
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
670000
CY2023Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
7000
CY2023Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
663000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
331000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
332000
ssy Number Of Taxing Authorities
NumberOfTaxingAuthorities
3
CY2020Q2 us-gaap Income Tax Examination Liability Refund Adjustment From Settlement With Taxing Authority
IncomeTaxExaminationLiabilityRefundAdjustmentFromSettlementWithTaxingAuthority
359000
ssy Sales Tax Receivable
SalesTaxReceivable
321000
CY2023Q4 ssy Sales Tax Receivable
SalesTaxReceivable
59000
CY2023Q4 us-gaap Sales And Excise Tax Payable Current And Noncurrent
SalesAndExciseTaxPayableCurrentAndNoncurrent
2615000

Files In Submission

Name View Source Status
0000950170-24-014629-index-headers.html Edgar Link pending
0000950170-24-014629-index.html Edgar Link pending
0000950170-24-014629.txt Edgar Link pending
0000950170-24-014629-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
ssy-20231231.htm Edgar Link pending
ssy-20231231.xsd Edgar Link pending
ssy-ex31_1.htm Edgar Link pending
ssy-ex31_2.htm Edgar Link pending
ssy-ex32_1.htm Edgar Link pending
ssy-ex32_2.htm Edgar Link pending
ssy-20231231_htm.xml Edgar Link completed